I like reporting on our sister industries, biotech and pharma. Their research can guide our efforts in the medical device industry. Below is a great report from Informa on how supply chain, manufacturing and sourcing for biotech/pharma been impacted by COVID – the link is below.
Key findings:
44% of respondents said that the COVID-19 pandemic had significant impact on their raw and ancillary materials and supply chain.
This was a surprise. So many medical technology clients reported a greater impact.
Less than a third of respondents to this market research said that they had suffered only ‘some impact’ from the pandemic.
63% of respondents said that the pandemic had caused them to re-evaluate or change their manufacturing or medical device supply strategies.
Greater than 50% of respondents are planning on developing second source vendors (an ouch that second source vendors had slipped in importance prior to COVID).
New risk mitigation strategies have increased in importance, as have demand forecasting rigor and working with local providers/vendors.
52% of respondents said that their companies’ partnering and licensing activities had increased since the COVID-19 pandemic began.
M&A activity among U.S. medical device, diagnostic, and digital healthcare companies are predicted to accelerate in 2021.
We help medtech companies lower M&A risk with M&A acquisition strategy research designed to help medical device clients assess the real clinical value of acquisitions, to uncover negatives that will drive down the value or hidden positive features that make the acquisition more valuable to the acquiring company.
Let’s connect – mshepherd@medi-vantage.com
CONTACT US
LOOKING FOR A PARTNER WITH KEY INSIGHTS FROM CLINICIANS & HOSPITAL ADMINISTRATORS AND HOSPITAL CFOS?
OUR LAST THREE PROJECTS WERE:
What price premium can be charged for an upgraded legacy product in a commodity space?
Medtech price sensitivity analysis - hospital administrators and CFOs
M&A due diligence analysis: pricing for a new disruptive product